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Abstract
Purpose To investigate the effects of soluble FGL2
(sFGL2) secreted by hepatic stellate cells (HSCs) on
immune suppression in cirrhotic patients with hepatocel-
lular carcinoma (HCC).
Methods Serum sFGL2 levels were examined by ELISA
in 40 patients with HCC, liver cirrhosis (LC) or chronic
HBV (CHB) infection. A double staining of the immuno-
fluorescence analysis of a-SMA and FGL2 was performed
in two cirrhotic liver specimens. The expression of FGL2
in the LX2 cell line was analyzed by immunofluorescence,
Western blot and flow cytometry. T-cells purified from
HCC patients using magnetic beads were cultured with
LX2 cells at different ratios with anti-CD3-stimulating or
FGL2-blocking antibodies. The proliferation index (PI) of
CD8 ? T cells was assessed by flow cytometry, and the
secretion of IFN-c was measured by ELISA.
Results sFGL2 levels are significantly higher in patients
with HCC or LC compared with those with CHB
(p = 0.0039/p = 0.0020). Among HCC patients, those
with cirrhosis exhibited significantly higher levels of
sFGL2 compared with non-cirrhotic individuals
(p = 0.0108). The expressions of FGL2 and a-SMA
overlapped in HSCs in liver specimens. FGL2 protein
secreted by LX2 cells inhibited T-cell proliferation of HCC
patients in a dose-dependent manner in vitro. The PI of
CD8 ? T cells was significantly enhanced following
addition of FGL2 antibody to the culture system (LX2/T-
cell ratio of 1:10, p = 0.002). The level of IFN-c in mixed
cultures was inversely correlated with the number of HSCs
and was reversed by incubation with FGL2 blocking
antibody.
Conclusion sFGL2 protein is a novel effector molecule of
activated HSCs, which suppresses CD8 ? T cell prolifer-
ation and interferon-c production, and it subsequently
might contribute to immune suppression during fibrosis and
tumorigenesis in the liver.
Keywords Soluble FGL2 protein  Hepatic stellate cells 
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
neoplasm in the world, and the third most common cause
of cancer-related deaths [1]. Hepatocellular carcinogenesis
is a multifactor, multistep process. The local cellular
immune status has been shown to correlate with HCC
invasion, recurrence and metastasis [2]. Thus, the HCC
immune microenvironment has recently been the focus of
extensive research.
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Despite their critical functions in the pathogenesis of
liver fibrogenesis, hepatic stellate cells (HSCs) have also
been shown to possess strong immunomodulatory activities
[3–5] and are closely associated with the occurrence and
development of HCC [6, 7]. Studies using immune-com-
petent mice and murine hepatic tumor cells revealed that
HCCs contain large number of a-SMA-positive HSCs and
that co-transplantation of HSCs, through an immunoregu-
latory form, significantly increases tumor volume [8].
Furthermore, in vitro studies demonstrate that this modu-
lator ability of HSCs is not only associated with a decrease
in T-cell infiltration and increased apoptosis of tumor-
infiltrating mononuclear cells, but also with the upregula-
tion of Treg cells and B7H1 expression [9]. While the
underlying mechanisms controlling this process remain
unclear, research in the field of HSC-mediated immuno-
suppression is becoming increasingly attractive.
FGL2/fibroleukin is a member of the fibrinogen-related
protein superfamily and exists in two forms [10]. In tumor
and reticuloendothelial cells, FGL2 is expressed as a
membrane-associated protein, which acts as a prothrom-
binase enzyme with the ability to generate thrombin
directly from prothrombin [11]. The procoagulant activity
of membrane-bound FGL2 (mFGL2) has been implicated
in the pathogenesis of several inflammatory disorders [12–
18]. However, soluble FGL2 (sFGL2), predominantly
secreted by T cells, in particular by Foxp3 ? Treg cells
[19], has previously been shown to act as an immuno-
modulator by inhibiting dendritic cell (DC) maturation and
T-cell proliferation through the FGL2-FccRIIB pathway
[20, 21]. Recent studies in HCV patients demonstrated that
plasma levels of sFGL2 were correlated with the stage of
fibrosis and were significantly higher in cirrhotic versus
non-cirrhotic patients [22]. Similarly, previous studies in
our laboratory also demonstrated that plasma sFGL2 levels
were positively correlated with inflammation activity
(G1–G3) and fibrosis (S0–S4) of the liver in autoimmune
hepatitis patients (unpublished data). Based on this, we
propose that sFGL2 is one of several effector factors
secreted by HSCs that play a pivotal role in the formation
of an immune-tolerant microenvironment in patients with
LC and HCC.
In this study, we identify a correlation between unreg-
ulated serum sFGL2 levels and HSC activation in HCC
patients. Additionally, we confirm that the sFGL2 protein
is expressed in the human HSC and LX2 cell lines. Finally,
we demonstrate that LX2 cells are capable of suppressing
the proliferation and IFN-c production of CD8 ? T cells
from HCC patients in vitro via sFGL2. Taken together,
these results suggest that targeting FGL2, which contrib-
utes to immune suppression during fibrosis and cancer,




Forty patients were recruited at Tongji Hospital between
March and November 2013 and were classified into four
groups: HBV infection, liver cirrhosis (LC), HCC, and
HCC with LC. Patients with HCC were recruited from the
Department of Hepatobiliary Surgery, while patients with
CHB or LC were recruited from the Department of Infec-
tious Diseases. The diagnosis of HCC was confirmed
pathologically by either surgical resection of liver tumors
or liver biopsies. Subjects were diagnosed with CHB if
they tested seropositive for HBsAg and serum amino-
transferases were consistently two-fold lower than the
upper limit. The diagnosis of cirrhosis was performed in
accordance with clinical, biochemical, ultrasonographic
and/or histological criteria. The information on the demo-
graphics, WBC count, ALT level, TBil, AFP, PT, HBV
viral load and anti-viral therapy of all patients is summa-
rized in Table 1. Blood samples were collected from HCC
patients before surgery or interventional procedures. None
of the cirrhotic patients had undergone splenectomy before.
This study was approved by the Ethics Committee of
Tongji Hospital.
Blood preparation and isolation of peripheral blood
mononuclear cells (PBMCs)
Whole blood was collected from patients and pelleted by
centrifugation (1,5009g, 10 min, 21 C) in heparinized
tubes. Plasma was subsequently collected and frozen at
-80 C until analysis. PBMCs were isolated by density
gradient centrifugation using Lymphoprep (Lympho-
PrepTM, Norway). Cells were washed twice with RPMI-
1640 (Gibco, USA) and resuspended in RPMI-1640 con-
taining 20 % (v/v) fetal bovine serum (FBS) (Gibco, USA)
for further analysis.
Cell culture and Western blot
LX2 cells (kindly provided by Prof. Dr. S. Friedman) were
cultured in DEME media containing 10 % (v/v) FBS
(Gibco, USA) and penicillin/streptomycin (100 ug/ml,
Invitrogen, Carlsbad, CA) at 37 C in 5 % CO2. Membrane
and cytosolic fractions were extracted from LX2 cells
using a plasma membrane protein extraction kit (Abcam,
Cambridge, MA). The expression of FGL2 was assessed by
Western blot as previously described [23]. Membranes
were first incubated with rabbit anti-Na ?/K ? ATPase
(1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), mouse anti-Fgl2 (1:400; Abnova, Taiwan, China)
and mouse anti-b-actin (1:3,000; Sigma, St Louis, MO,
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USA) primary antibodies and subsequently with either goat
anti-mouse (1:2,500; Bio-Rad Laboratories, Veenendaal,
The Netherlands) or goat anti-rabbit (1:5,000; Santa Cruz
Biotechnology, CA, USA)-horseradish peroxidase conju-
gated secondary antibodies. Membranes were incubated
with ECL-Plus reagent (Amersham, Piscataway, NJ), and
chemiluminescence was detected using BioMax MR Film
(Kodak, Rochester, NY).
Immunofluorescence and flow cytometric staining
of FGL2
For immunofluorescence analysis, two cirrhotic liver tissues
were fixed for 48 h in 10 % formalin and embedded in paraffin
wax before sectioning. Sections of 4 lm thickness for each
specimen were prepared on silanized slides. The slides were
washed with PBS and then blocked with Protein Block Serum-
Free solution. A suspension of LX2 cells (1 9 106 cells/ml)
was dripped onto polylysine pre-treated slides and incubated
for 10 min. Cells were then fixed with ice-cold acetone for
15 min on ice, then were blocked with 5 % (w/v) bovine
serum albumin (BSA). Both slides were incubated with mouse
anti-FGL2 [1:250, diluted in PBS containing 1 % (w/v) BSA]
overnight at 4 C, then washed in PBS, incubated with PE-
conjugated goat anti-mouse IgG secondary antibody (1:100,
diluted in 1 % BSA-PBS, eBioscience, USA) and FITC-
conjugated goat anti-human a-SMA antibody (1:100, 1 %
BSA in PBS, ebioscience, USA) at room temperature for 1 h.
The cells were then washed and stained with propidium iodide
(ebioscience, USA) for 10 min. Finally, the cells were washed
in PBS and slides were mounted using anti-fade fluorescence
glycerin buffer. Cells were visualized by fluorescence
microscopy (Olympus IX51, Japan).
For flow cytometric analysis, LX2 cells (1 9 106 cells)
were collected in FACS tubes by centrifugation. One set of
tubes in group 2 was resuspended in 100 ll of Perm/
WashTM solution (BD, USA) to allow fixation/permeabi-
lization of cells, while operation of rupturing membranes
was not used for tubes in group 1. Cells were then incu-
bated with mouse anti-FGL2 antibody (1:100, 1 lg) or
normal goat serum as an isotype control at 37 C for 1 h in
the dark. Cells were then washed with 19 Perm/WashTM
solution (1 ml) and incubated with FITC-conjugated goat
anti-mouse IgG 1 antibody (1:100) at 37 C for 30 min in
the dark. Cells were washed two times with PBS and
resuspended in 300 ul for analysis by a FACSAria Flow
Cytometer (BD Biosciences).
Isolation of T cells from PBMCs
T cells were isolated from PBMCs using the human pan
T-cell isolation kit (Miltenyi Biotec, German) and a Midi
Macs separator unit, in accordance with the manufacturer’s
instructions. In certain experiments, total PBMCs were
depleted of non-T cells, and CD3 ? T cells were selected.
Proliferation and functional analysis of CD8 ? T Cells
To analyze the PI, CD8 ? T cells were labeled with CFSE
(Invitrogen, USA) in accordance with the manufacturer’s
Table 1 Data of patients
Characteristics CHB (8) LC (11) HCC with LC (10) HCC (11)
Age (years) 43.5 ± 10.3 48.2 ± 11.6 47.3 ± 7.9 45.5 ± 11.7
Gender (M:F) 4:4 5:6 8:2 8:3
WBC count (109/l) 6.2 ± 2.3 6.1 ± 2.2 6.0 ± 2.2 6.3 ± 2.2
ALT (u/l) 38.1 ± 31.1 35.0 ± 48.7 53.1 ± 47.7 41.2 ± 63.0
Tbil (umol/l) 12.6 ± 4.1 21.6 ± 17.5 20.2 ± 19.1 13.1 ± 6.0
PT (s) 13.2 ± 0.7 17.2 ± 1.8 15.1 ± 1.3 13.7 ± 0.9
AFP (ug/l)



















Antiviral treatment 1(NA)/8 3(NA)/11 3(2NA 1IFN)/10 3(NA)/11
Child-Pugh score 7.7 ± 2.4 6.0 ± 1.0
The data are presented as the mean ± SD
WBC white blood cell, ALT alanine transaminase, Tbil total bilirubin, PT prothrombin time, AFP a-fetoprotein
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instructions. Cells were washed with RPMI-1640 supple-
mented with 10 % (v/v) FBS, and an aliquot of cells was
stained with PE-anti-human CD8a (Biolegend, USA). Cells
were analyzed by flow cytometry to set the starting fluo-
rescence intensity to that of the parent generation. The
remaining cells were seeded in flat-bottomed 96-well plates
(1 9 106 cells/well) and cultured with LX2 cells for 5 days
in medium containing 20 % (v/v) FBS (as described
below). Cells were then stained with PE-anti CD8 antibody
and analyzed by flow cytometry. The PI was determined
using the Becton-Dickinson ModFit software.
T cells and LX2 cells were cultured at different ratios in
medium containing 20 % (v/v) FBS and recombinant IL-2
(2 U/well, R&D Systems, USA) with either anti-CD3 antibody
(CD3 stimulation group, 1 pg/ml) or FGL2 antibody (FGL2
blocking group, 5 pg/ml). Negative control cells were cultured
without the addition of antibodies (blank group) or IgG2a
isotype antibodies (Abcom, USA). Each treatment group was
performed in duplicate. After 48 h, culture supernatants were
collected for detection of interferon (IFN)-c levels by ELISA
and fresh medium supplemented with stimulants was added for
further culturing of cells. After 5 days in culture, cells were
collected and CD8 ? T-cell proliferation analysis was per-
formed by flow cytometry (BD FACS Canto II).
Detection of sFGL2 and IFN-c levels by ELISA
FGL2 levels of patient serum and cell culture supernatants
were determined using the LEGEND MAXTM Human
FGL2 ELISA Kit in accordance with the manufacturer’s
instructions (Biolegend, San Diego, CA, USA). IFN-c
levels in culture supernatants from the CD3 stimulation
group, FGL2 blocking group and blank group were
detected using an ELISA kit (Dakewe, Beijing).
Statistical analysis
All graphs were constructed and analysis performed using
GraphPad Prism 5 software. Data are expressed as
mean ± standard deviation (SD). Differences in serum
FGL2 levels between various groups were analyzed by
one-way ANOVA or Kruskal-Wallis test. Statistical anal-
yses of CD8 ? T-cell proliferation and IFN-c production
were analyzed by paired Student’s t test. The level of
significance was set at p \ 0.05.
Results
Patient characteristics
The sociodemographic and clinical characteristics of all
study groups are displayed as the mean ± SD and are
presented in Table 1. No significant differences in the age,
gender, white blood cell (WBC) count, alanine transami-
nase (ALT), total bilirubin (TBil), prothrombin time (PT)
or HBV viral load were observed between groups, while no
significant differences in the Child-Pugh scores were found
in LC patients with or without HCC. Alpha-fetoprotein
(AFP) levels were elevated in patients with HCC compared
with patients with CHB and LC (p = 0.000 for HCC vs.
CHB and LC).
Patient serum sFGL2 levels
The sFGL2 levels in CHB patients (n = 8), LC patients
(n = 11), HCC patients (n = 11 with LC, n = 10 without
LC) are displayed in Fig. 1. Statistical analysis revealed that
the serological levels of sFGL2 in HCC and LC patients were
significantly higher than in CHB control groups (41.84 ±
17.64 ng/ml/50.61 ± 22.69 ng/ml vs. 23.30 ± 6.19 ng/ml,
p = 0.0039/p = 0.0020). Among HCC patients, the level of
sFGL2 in patients with cirrhosis was significantly higher in
than those without cirrhosis (51.61 ± 20.30 ng/ml vs.
32.81 ± 8.81 ng/ml, p = 0.0108). In contrast, among LC
patients, no significant differences in sFGL2 levels were
observed between those patients with HCC and non-HCC.
Expression of FGL2 in liver tissue from cirrhotic
patient
A double staining of the immunofluorescence analysis of a-
SMA and FGL2 was performed to detect the co-localiza-
tion of FGL2 and a-SMA in HSCs. a-SMA (Fig. 2a, green)
expression was found in sinusoid areas as well as periportal
areas, representing a marker of activated HSCs. FGL2
(Fig. 2a, red) could be found at the same area. The merged
images indicate the co-localization of FGL2 and a-SMA,
revealing that FGL2 was expressed within HSCs.
Fig. 1 Serum levels of sFGL2 in 8 CHB patients, 11 LC patients and
21 HCC patients (11 with and 10 without LC). Individual values are
plotted with mean ± SD shown for each group. Values of p are
indicated for comparisons of the four groups
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Expression of FGL2 in the LX2 cell line
Human LX2 cells were used as a research tool to study the
localization of FGL2 in HSC in vitro. Cellular extracts
were obtained and membrane and cytosolic fractions were
separated using a plasma membrane protein extraction kit.
As shown in Fig. 2b, Western blot analysis revealed that
FGL2 protein is present in the cellular cytoplasm, but not
in the membrane. Intracellular staining for FGL2 identified
expression only following permeabilization (Fig. 2c), as
assessed by flow cytometry. Furthermore, immunofluores-
cence analyses revealed that while a-SMA was expressed
in both the cytoplasm and the membrane of LX2 cells
(Fig. 2d, green), sFGL2 protein was predominantly
expressed in the cytoplasm of cells (Fig. 2d, red). These
data confirm the constitutive expression of FGL2 in LX2
cells and suggest that sFGL2 exists largely in the soluble
form Fig. 3.
Fig. 2 Expression of sFGL2 in liver tissue and human LX2 cells.
a Double staining immunofluorescence analysis indicates the co-
localization of a-SMA (green) and FGL2 (red). b Western blot
analysis showing FGL2 expression in cytosol but not membrane
fractions. Na ? K ? ATPase used as a positive control for membrane
protein; b intracellular staining of FGL2 protein in LX2 cells. FGL2
expression (upper case) was detected by flow cytometry after
permeabilizationn; c double staining for a-SMA (green) and FGL2
(red). a-SMA-positive expression represents activated HSCs, and
sFGL2 is predominantly expressed in the interior of cells. (Color
figure online)
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Fig. 3 hepatic stellate cells (HSCs) inhibit the proliferation of
CD8 ? T cells via sFGL2. The T cells isolated from hepatocellular
carcinoma (HCC) patients were co-cultured with LX2 cell lines. a An
increased amount of sFGL2 in the culture supernatant was detected by
ELISA as the number of LX2 cells increased. (The supernatant of
1.2 9 106 Treg was used as a positive control, and the culture
medium was the negative control.) b Flow cytometry analysis of the
CD8 ? T cell proliferation index; c proliferation index of the
CD8 ? T cells from each sample in CD3 stimulation, FGL2
blocking; blank control groups at different LX2/T-cell ratios.
d Data are expressed as the mean ± SD. Values of p are indicated
for comparisons of the four groups
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LX2 cells inhibit the proliferation of CD8 ? T cells
via sFGL2
LX2 cells were co-cultured with T cells at various ratios
(1:10–1:1,000) and divided into four groups (CD3 stimu-
lation group, FGL2 blocking group, IgG isotype group and
blank group). An increased amount of sFGL2 was evi-
denced in the culture supernatant as the ratio of LX2 cells
to T cells increased (Fig. 2a). After co-culturing for 5 days,
the PI CD8 ? T cells were analyzed by flow cytometry
using the Becton-Dickinson ModFit software (Fig. 2b).
The PI of CD8 ? T cells from each group is shown in
Fig. 2c (a–c). Statistical analysis revealed that the inhibi-
tory effect of LX2 cells on T-cell proliferation was aug-
mented in accordance with the increase in the LX2/T-cell
ratio (p = 0.019). The PI of CD8 ? T cells in the FGL2
blocking group was higher than that in the IgG isotype-
treated group at an LX2/T-cell ratio of 1:10 (3.52 ± 0.96
vs. 2.81 ± 0.62, p = 0.002) and lower than that in the CD3
stimulation group in all samples (p = 0.045 at 1:1,000;
p = 0.06 at 1:100 and p = 0.017 at 1:10) (Fig. 2d).
LX2 decreases IFN-c production via sFGL2
IFN-c levels in culture supernatants were detected by
ELISA. The average OD values in each group are shown in
Fig. 4a. We observed that the average IFN-c levels in the
control-treated group were lower than those in the CD3
stimulation group in LX2/T-cell mixed cultures (all
p \ 0.001). The OD values in the blank group decreased
from 1.57 ± 0.46 at an LX2/T-cell ratio of 1:1,000 and to
0.58 ± 0.21 at an LX2/T-cell ratio of 1:10 (p = 0.013). No
significant differences in IFN-c levels were observed
between the FGL2 blocking group (1.23 ± 0.36) and
control group at an LX2/T-cell ratio of 1:1,000. However,
when the ratio of LX2 cells was increased (1:10), the
secretion of IFN-c in the FGL2 blocking group markedly
increased compared with IgG isotype-treated cells
(0.575 ± 0.145 vs. 1.35 ± 0.145, p = 0.004, Fig. 4a)
(143.95 ± 33.32 vs. 289.71 ± 12.67 pg/ml, p = 0.012,
Fig. 4b). In contrast, no significant differences in IFN-c
levels were observed between the FGL2 blocking group
and CD3 stimulation group (367.58 ± 54.31 pg/ml,
Fig. 4b). These results indicate that HSCs downregulate the
secretion of the IFN-c by T cells, an effect that may be
reversed by blocking with anti-FGL2 antibody.
Discussion
The majority of HCC patients exhibit underlying chronic
liver disease and marked impairment in T-cell responses at
the baseline level, correlating with tumor burden and poor
outcome [24]. LC is the main risk factor underlying the
development of HCC, and to date, there is a significant
amount of literature highlighting the crosstalk between
tumor cells, HSCs and their surrounding microenvironment
[25]. Recent reports indicate that HSCs exhibit potent
inhibitory activity against the T-cell response that may
impair, at least in part, hepatic immune homeostasis and
tumor progression in the liver. However, to date, the
mechanisms underlying this process remain unclear.
FGL2, which shares 36 % protein homology with the
fibrinogen b- and c-chains, has previously been shown to
possess immunomodulatory activity by inhibiting DC
maturation and subsequent T-cell proliferation and by
polarizing T-helper cell activity toward a type 2 cytokine
response [26]. In this study, we demonstrate that patients
with cirrhosis express significantly higher levels of FGL2
compared with patients without cirrhosis, independently of
whether they have HCC, suggesting that the presence of
activated HSCs may account for the high levels of FGL2.
Fig. 4 Detection of the IFN-c level by using ELSIA. The cells were
treated and cultured as described in Materials and methods. The
supernatants were collected and analyzed. a The average A values of
IFN-c in the co-culture mixed supernatants at the T/HSCs ratio varied
from 10:1 to 1,000:1. b The levels of IFN-c (pg/ml) detected at a
T/HSCs ratio of 100:1. The data are expressed as mean ± SD. Values
of p are indicated for comparisons of the four groups
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No degree of cirrhosis had a positive correlation with the
sfgl2 level according to this study, perhaps because of the
limited number of patients. However, their correlation has
been reported previously by Foerster et al. [27]. The
fibrosis stage and FGL2 plasma levels were assessed in 71
out of 80 patients with HCV infection. Plasma FGL2 levels
were significantly higher in patients with advanced fibrosis
(stage 3–4) compared with patients with mild (stage \1)
and moderate fibrosis (stage 2). In addition, analysis of
plasma levels of FGL2 according to the activity grade
showed a significant difference in patients with higher
inflammation as assessed by activity grade (grade [2)
compared with those with a lower grade of inflammation
(grade \2).
To better demonstrate the correlation of sFGL2
expression with cirrhosis, a double staining of the immu-
nofluorescence analysis of a-SMA and FGL2 in liver
specimens from two cirrhotic patient was performed. The
merged images indicated the co-localization of FGL2 and
a-SMA, revealing that FGL2 was expressed within HSCs.
The human LX2 cell line is a well-characterized HSC line
that recapitulates many features of the activated HSC [28].
We observed high expression of a soluble form of FGL2 in
LX2 cells. HSCs have previously been shown to exhibit
features of antigen-presenting cells and to stimulate lym-
phocyte proliferation [29]. Our study showed an increased
amount of sFGL2 in the culture supernatant as the ratio of
LX2 cells to T cells increased, and correspondingly, LX2
cells inhibit CD8 ? T-cell proliferation in a dose-depen-
dent manner. Blocking sFGL2 with anti-FGL2 antibodies
led to an increase in CD8 ? T cell proliferation. Moreover,
we observed that the level of IFN-c, which is presumably
secreted by CD8 ? T cells and reflects the strength of the
immune response, is inversely correlated with the number
of HSCs and significantly increases in the sFGL2 blocking
group in the mixed culture. Since there is no previous
evidence to suggest that LX2 cells produce IL-2 [30] or
IFN-c [31], CD8 ? T lymphocytes are still considered
major sources of IFN-c in the co-culture system. In our
study, the suppressive effect of HSCs was abolished and
the secretory level of IFN-c increased following the addi-
tion of FGL2 antibodies to the culture system. These data
strongly suggest that sFGL2 secreted by HSCs may be a
critical factor underlying the inhibitory effect by sup-
pressing the proliferation of CD8 ? T cells.
Multiple mechanisms may be involved in HSC-induced
immune tolerance. Jiang et al. [32], observed that HSCs
induce apoptosis of conventional CD4 ? T cells, primarily
via a Fas-FasL-dependent mechanism. A study by Yu MC
et al. [33] revealed that quiescent HSCs express low levels
of B7-H1. Expression of B7-H1 in HSCs notably increases
following exposure to various stimuli, and inhibition of B7-
H1 may partially reduce HSC-induced T-cell apoptosis
[34]. However, direct contact may not account for the
complexity of interactions between HSCs and responder T
cells [35]. Our study provides new evidence that sFGL2, as
a soluble factor secreted by activated HSCs, represents an
additional mechanism accounting for the immune-sup-
pressive effect of these cells. Furthermore, Dangi et al. [36]
concluded LPS-stimulated HSCs may promote hepatic
tolerogenicity by influencing naturally occurring immuno-
suppressive CD4 ? CD25 ? Foxp3 ? regulatory T cells,
and it has been reported that HSCs could induce
CD14 ? HLA-DR-/low myeloid-derived suppressor cells
from mature peripheral blood monocytes via CD44 [37,
38]. In light of the close relationship between sFGL2 and
Treg or DC cells, we propose that HSCs may affect T cells,
in addition to other immune cells, via sFGL2. Our previous
work [39] demonstrated that there was no significant dif-
ference in IFN-c production of CD8 ? T cells when only
PBMCs were cultured in the absence or presence of FGL2
Ab, which suggested Treg cells did not significantly reg-
ulate CD8 ? T cells. Further investigations are required to
determine the detailed mechanism of how LX2-expressed
FGL2 exerts its effect on CD8 ? T cells. It could be either
through the FGL2-FccRIIB pathway directly or by inhib-
iting the maturation of DC or increasing the function of
Treg indirectly.
In conclusion, our study demonstrated the activated
HSC cells are capable of secretion of sFGL2. The HSC-
produced sFGL2 is a novel functional molecule exerting its
negative regulation on CD8 ? T cells. This finding pro-
vides new insight into understanding the immune response
during hepatic fibrosis and tumorigenesis.
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